Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

REGN vs UNOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: REGN 6 – 0 UNOV Matrix Metrics: REGN 8 – 2 UNOV

As of Nov 16, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). REGN carries a Unified Composite Score of 38.6/100 (SELL) at $952.40 (15.3x Forward P/E, 30.4% operating margin), whereas UNOV carries 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While UNOV currently prints a higher short-term Unified Composite Score (58.7/100 HOLD vs. REGN 38.6/100 SELL), REGN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (30.4% vs. N/A operating margin) and revenue trajectory (+36.3% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About REGN vs UNOV
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$952.40
-0.32% 1D
Market Cap $98.8B
TTM Revenue $16.9B
Forward P/E 15.3x
Beta / 30D Vol 0.33β · 55% Vol
Unified Composite Score
38.6 / 100 SELL
Tech 23.0 Fund 43.0 Flow 67.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.5% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $887.40 · SMA50: $818.67
UNOV Cboe BZX
Innovator U.S. Equity Ultra Buffer ETF - November
Pharmaceutical Preparations
$41.13
-0.95% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.46β · 11% Vol
Unified Composite Score
58.7 / 100 HOLD
Tech 48.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.3 · SMA20: $41.59 · SMA50: $41.48

6-Pillar Scorecard Institutional Category Breakdown (REGN 6 – 0 UNOV)

Columns: Metric · REGN · UNOV
1. Valuation Multiples REGN
Forward P/E 15.3x N/M
Trailing P/E 21.1x N/M
PEG Ratio 1.16x N/M
EV / Revenue 5.8x N/M
2. Growth & Scale REGN
Revenue Growth (YoY) +36.3% N/A
Earnings Growth (YoY) +35.5% N/A
TTM Revenue (USD) $16.9B N/A
Market Cap $98.8B N/A
3. Profitability & Quality REGN
Gross Margin 46.7% N/A
Operating Margin 30.4% N/A
Net Profit Margin 28.5% N/A
Return on Equity (ROE) 14.9% N/A
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) $3.63B N/A
Cash Flow Margin 21.5% N/A
Net Cash / Leverage $952M Net Cash N/A ROE
Dividend Yield 0.39% None (0.00%)
5. Options & Positioning REGN
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 35.9% (6th %ile) N/A (N/A)
Put/Call OI Skew 0.38x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat REGN
OpEx & R&D Intensity 16.3% of Rev ($2.75B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: REGN (8) vs UNOV (2)
Institutional Metric REGN UNOV Criterion Row Edge
Market Capitalization
Scale
$98.8B N/A Larger Scale REGN
Trailing P/E Ratio
Valuation
21.1x N/M Lower Multiple REGN
Forward P/E Ratio
Valuation
15.3x N/M Lower Multiple REGN
Revenue Growth (YoY)
Growth
+36.3% N/A Higher Growth REGN
Operating Margin (TTM)
Profitability
30.4% N/A Higher Margin REGN
Net Profit Margin
Profitability
28.5% N/A Higher Margin REGN
Return on Equity (ROE)
Capital Efficiency
14.9% N/A Higher ROE REGN
52-Week Range Position
Momentum
90% ($592–$992) 84% ($37–$42) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
0.33β · 55% Vol 0.46β · 11% Vol Lower Realized Risk UNOV
Unified Institutional Score
Composite Signal
38.6 / 100 (SELL) 58.7 / 100 (HOLD) Higher Composite UNOV
Trailing 12M Revenue (USD)
Operating Scale
$16.9B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.16x PEG · 5.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.63B ($952M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REGN +21.41 pp
REGN: +20.44% · UNOV: -0.97%
3M Horizon REGN +17.11 pp
REGN: +17.55% · UNOV: +0.44%
6M Horizon REGN +47.83 pp
REGN: +51.25% · UNOV: +3.42%
1Y Horizon REGN +27.51 pp
REGN: +37.04% · UNOV: +9.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REGN vs UNOV. Trailing 12-month operating profitability (REGN 30.4% vs UNOV N/A) and valuation multiples (REGN 15.3x vs UNOV N/M Forward P/E) are benchmarked directly in Pillar 4 below.

REGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$16.9B
Gross Margin46.7%
Op. Margin30.4%
ROE / Fwd P/E14.9% · 15.3x
UNOV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
REGN BREAKOUT
52d in phase · OBV ACCUMULATION
Current IV 35.9%
IV Percentile 6th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $98.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published
UNOV Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ REGN vs UNOV Key Questions & Quantitative Answers

As of Nov 16, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). REGN carries a Unified Composite Score of 38.6/100 (SELL) at $952.40 (15.3x Forward P/E, 30.4% operating margin), whereas UNOV carries 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While UNOV currently prints a higher short-term Unified Composite Score (58.7/100 HOLD vs. REGN 38.6/100 SELL), REGN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (30.4% vs. N/A operating margin) and revenue trajectory (+36.3% vs. N/A YoY).

REGN leads the Growth & Scale pillar: REGN posts +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin), compared with UNOV at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, REGN generates $16.9B in USD-normalized revenue versus N/A for UNOV. In operating R&D and SG&A reinvestment, REGN deploys 16.3% of Rev ($2.75B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for UNOV.

REGN screens cheaper on headline valuation multiples. REGN trades at 15.3x Forward P/E, 21.1x Trailing P/E, 1.16x PEG, and 5.8x EV/Revenue (21.5% FCF margin), whereas UNOV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REGN (14.9% ROE) versus UNOV (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, REGN carries 35.9% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.33β · 55% Vol realized risk). By comparison, UNOV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 11% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.